Metoclopramide Hameln Pharma (Metoclopramide Hydrochloride Monohydrate)

Metoclopramide works by antagonizing dopamine D2 receptors in the chemoreceptor trigger zone of the brain, which reduces the central stimulus for vomiting. It also blocks peripheral D2 receptors, increasing acetylcholine release and promoting coordinated stomach contractions, thereby speeding gastric emptying. Weak 5‑HT3 antagonism adds to its anti‑nausea effect.

The appropriate dose of Metoclopramide Hameln Pharma is determined by the prescribing clinician based on the specific indication, patient age, weight, renal and hepatic function, and route of administration. Dosage regimens vary for acute nausea, postoperative prophylaxis, or chronic gastroparesis, and should follow local prescribing guidelines.

Safety data for metoclopramide in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus. It is excreted in breast milk, so caution is advised for nursing mothers, and a healthcare professional should evaluate the risk‑benefit balance.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Metoclopramide differs from many antiemetics by combining dopamine antagonism with pro‑kinetic activity, making it useful for both nausea control and gastric motility disorders. Compared with pure 5‑HT3 antagonists, it offers additional benefit in gastroparesis but carries a higher risk of extrapyramidal side effects, so patient selection is important.

Metoclopramide Hameln Pharma should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Ensure the container is tightly closed and keep the product away from extreme temperatures or direct sunlight to maintain stability.

The product is supplied as an injectable solution for intramuscular or intravenous administration. The route, injection site, and infusion rate are determined by the prescribing clinician based on the indication and patient condition. Proper aseptic technique and dosage calculations are essential for safe administration.

Serious risks include extrapyramidal reactions such as acute dystonia or tardive dyskinesia, neuroleptic malignant syndrome, severe depression, seizures, and cardiac arrhythmias including QT prolongation. Patients should be monitored closely for these events, especially with high doses, prolonged therapy, or when interacting drugs increase risk.

Metoclopramide should be avoided in patients with known hypersensitivity to the drug, in those with a history of severe extrapyramidal reactions, in individuals taking MAO inhibitors, and in patients with uncontrolled epilepsy or significant cardiac conduction abnormalities. Caution is also advised for the elderly and for patients with renal or hepatic impairment.